Gene · 53637
Papers1,387
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,387
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches. | Biomol Ther (Seoul) | 2025 | 40827120 | PubTator, text mining | PubMed |
| Role of vitamin D and omega 3 fatty acids in improving HDL biogenesis among multiple sclerosis patients via orchestrating CHROME/APOA1-AS/ABCA1/APOA1 milieu. | J Nutr Biochem | 2025 | 40532959 | PubTator, text mining | PubMed |
| Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis. | J Clin Med | 2025 | 40507651 | PubTator, text mining | PubMed |
| Design and Synthesis of Novel PET Radiotracers for Imaging Sphingosine-1-Phosphate Receptor 5 (S1PR5) in the Brain. | J Med Chem | 2025 | 40476381 | PubTator, text mining | PubMed |
| Characterization of functionally relevant G protein-coupled receptors in endometriotic epithelial cells. | Cell Signal | 2025 | 40381972 | PubTator, text mining | PubMed |
| Drug-targeted Mendelian randomization analysis combined with transcriptome sequencing to explore the molecular mechanisms associated with cognitive impairment. | J Alzheimers Dis | 2025 | 40267292 | PubTator, text mining | PubMed |
| Hedgehog pathway inhibitor HhAntag suppresses virus infection via the GLI-S1PR axis. | Cell Signal | 2025 | 40239727 | PubTator, text mining | PubMed |
| Transcriptional signature of rapidly responding NK cells reveals S1P5 and CXCR4 as anti-tumor response disruptors. | Sci Rep | 2025 | 40155684 | PubTator, text mining | PubMed |
| Siponimod inhibits microglial inflammasome activation. | Neurosci Res | 2025 | 39921000 | PubTator, text mining | PubMed |
| Negative regulation of cannabinoid receptor 2‑induced tumorigenic effect by sphingosine‑1‑phosphate receptor 5 activation. | Oncol Rep | 2025 | 39918009 | PubTator, text mining | PubMed |
| Revealing the role of natural killer cells in ankylosing spondylitis: identifying diagnostic biomarkers and therapeutic targets. | Ann Med | 2025 | 39853176 | PubTator, text mining | PubMed |
| Assessment of a 6-arylaminobenzamide lead derivative as a potential core scaffold for S1P5 positron emission tomography radiotracer development. | Bioorg Med Chem | 2025 | 39798239 | PubTator, text mining | PubMed |
| Unique pharmacological properties of etrasimod among S1P receptor modulators. | FEBS Open Bio | 2025 | 39564958 | PubTator, text mining | PubMed |
| Identifying key genes and functionally enriched pathways in acute myeloid leukemia by weighted gene co-expression network analysis. | J Appl Genet | 2025 | 38977582 | PubTator, text mining | PubMed |
| Identification of Hub Genes and Immune Infiltration in Coronary Artery Disease: A Risk Prediction Model. | J Inflamm Res | 2024 | 39553308 | PubTator, text mining | PubMed |
| Progress in Precision Medicine for Head and Neck Cancer. | Cancers (Basel) | 2024 | 39518152 | PubTator, text mining | PubMed |
| Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management. | Drugs | 2024 | 39322927 | PubTator, text mining | PubMed |
| Sphingosine 1-phosphate protective effect on human proximal tubule cells submitted to an in vitro ischemia model: the role of JAK2/STAT3. | J Physiol Biochem | 2024 | 39155330 | PubTator, text mining | PubMed |
| S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia. | OMICS | 2024 | 38986084 | PubTator, text mining | PubMed |
| Novel Compounds as S1P5 Modulators for Treating Neurodegenerative Diseases. | ACS Med Chem Lett | 2024 | 38894913 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53637/papers?page=3